Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient ...

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.

Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gibson SOLA platform at R&D ...

Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

Eton Pharmaceuticals’ NDA for Khindivi, an oral solution of hydrocortisone, has received US Food and Drug Administration (FDA ...